TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenax Therapeutics Inc (TENX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there is potential for significant upside due to the Phase 3 readout of TNX-103 in Q3 2026, the current technical indicators, lack of immediate positive trading signals, and weak financial performance suggest a cautious approach. The stock may be better suited for high-risk, speculative investors rather than a beginner with a long-term focus.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 30.142, and moving averages are converging, providing no clear trend. The stock is trading near its S1 support level of 13.552, with resistance at 16.027. Overall, the technical indicators suggest a weak and uncertain price trend.
Analysts have initiated coverage with high price targets ($27-$
and positive outlooks, citing the potential of TNX-103 as a multi-billion dollar drug.
The pivotal Phase 3 readout in Q3 2026 could act as a major catalyst if successful.
Weak financial performance with no revenue and significant net losses (-$15.54M in Q4 2025).
Lack of recent news or influential trading activity from insiders, hedge funds, or politicians.
Technical indicators show bearish momentum and no clear upward trend.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of -$15.54M, though the loss improved by 147.96% YoY. EPS also improved to -0.38, up 123.53% YoY. However, the company remains unprofitable with no gross margin.
Analysts have issued positive ratings, with Cantor Fitzgerald and Guggenheim assigning Overweight/Buy ratings and price targets ranging from $27 to $35. They highlight the potential of TNX-103 and the upcoming Phase 3 readout as key drivers for the stock. However, they also acknowledge the high-risk, high-reward nature of the investment.
